Tseng TC - Search Results

1

Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.

Huang SC, Su TH, Tseng TC, Chen CL, Hsu SJ, Liao SH, Hong CM, Liu CH, Lan TY, Yang HC, Liu CJ, Chen PJ, Kao JH. Huang SC, et al. Among authors: tseng tc. Hepatol Int. 2023 Oct;17(5):1139-1149. doi: 10.1007/s12072-023-10545-6. Epub 2023 May 29. Hepatol Int. 2023. PMID: 37247045

2

Sequential combination therapy for chronic hepatitis B: more challenges to be tackled.

Tseng TC, Liu CJ, Kao JH. Tseng TC, et al. Am J Gastroenterol. 2007 Jul;102(7):1544; author reply 1545. doi: 10.1111/j.1572-0241.2007.01261.x. Am J Gastroenterol. 2007. PMID: 17593169 No abstract available.

3

Subgenotypes of hepatitis B virus genotype C do not correlate with disease progression of chronic hepatitis B in Taiwan.

Tseng TC, Liu CJ, Chen PJ, Lai MY, Lin CL, Kao JH, Chen DS. Tseng TC, et al. Liver Int. 2007 Sep;27(7):983-8. doi: 10.1111/j.1478-3231.2007.01546.x. Liver Int. 2007. PMID: 17696938

4

HBV genotype and clinical outcome of chronic hepatitis B: facts and puzzles.

Tseng TC, Kao JH. Tseng TC, et al. Gastroenterology. 2008 Apr;134(4):1272-3; author reply 1273. doi: 10.1053/j.gastro.2007.12.046. Gastroenterology. 2008. PMID: 18395116 No abstract available.

5

A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients.

Tseng TC, Liu CJ, Wang CC, Chen PJ, Lai MY, Kao JH, Chen DS. Tseng TC, et al. Liver Int. 2008 Aug;28(7):1034-41. doi: 10.1111/j.1478-3231.2008.01766.x. Epub 2008 May 19. Liver Int. 2008. PMID: 18492018

6

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.

Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, Hsu CS, Tseng TC, Wang CC, Lai MY, Chen JH, Chen PJ, Chen DS, Kao JH. Liu CH, et al. Among authors: tseng tc. Clin Infect Dis. 2008 Nov 15;47(10):1260-9. doi: 10.1086/592579. Clin Infect Dis. 2008. PMID: 18834319 Clinical Trial.

7

HBsAg seroclearance: the more and earlier, the better.

Tseng TC, Kao JH. Tseng TC, et al. Gastroenterology. 2009 May;136(5):1842-3; author reply 1843-4. doi: 10.1053/j.gastro.2008.12.074. Epub 2009 Mar 18. Gastroenterology. 2009. PMID: 19303023 No abstract available.

8

Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.

Tseng TC, Liu CJ, Wang CC, Chen PJ, Lai MY, Chen DS, Kao JH. Tseng TC, et al. Antivir Ther. 2009;14(2):203-10. Antivir Ther. 2009. PMID: 19430095

9

Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease.

Wang CC, Lin SK, Tseng YF, Hsu CS, Tseng TC, Lin HH, Wang LY, Kao JH. Wang CC, et al. Among authors: tseng yf, tseng tc. J Gastroenterol Hepatol. 2009 Aug;24(8):1411-6. doi: 10.1111/j.1440-1746.2009.05872.x. J Gastroenterol Hepatol. 2009. PMID: 19702910

10

Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C.

Hsieh TH, Tseng TC, Liu CJ, Lai MY, Chen PJ, Hsieh HL, Chen DS, Kao JH. Hsieh TH, et al. Among authors: tseng tc. Antivir Ther. 2009;14(8):1157-63. doi: 10.3851/IMP1454. Antivir Ther. 2009. PMID: 20032545

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

241 results

Search Page